KalVista Pharmaceuticals, Inc.
Prognozy (mln)
| Okres |
2024-04-30 |
2025-04-30 |
2026-04-30 |
2027-04-30 |
2028-04-30 |
2029-04-30 |
2030-04-30 |
| Przychód (średnia) |
4.46 |
4.46 |
34.69 |
111.43 |
228.21 |
330.14 |
427.55 |
| Przychód Δ r/r |
0.00% |
0.10% |
677.08% |
221.18% |
104.81% |
44.67% |
29.50% |
| Przychód (min) |
3.16 |
3.16 |
29.11 |
83.16 |
222.22 |
233.72 |
302.67 |
| Przychód (max) |
6.10 |
6.11 |
47.41 |
142.94 |
234.19 |
451.55 |
584.77 |
| EBITDA (średnia) |
2.68 |
2.68 |
20.82 |
66.86 |
136.92 |
198.09 |
256.53 |
| EBIT (średnia) |
2.68 |
2.68 |
20.82 |
66.86 |
136.92 |
198.09 |
256.53 |
| EBIT % |
60.00% |
60.00% |
60.00% |
60.00% |
60.00% |
60.00% |
60.00% |
| Zysk netto (średni) |
-151.00 |
-183.44 |
-175.73 |
-120.61 |
-9.49 |
70.38 |
143.99 |
| Zysk netto % |
-3385.37% |
-4108.95% |
-506.52% |
-108.24% |
-4.16% |
21.32% |
33.68% |
| EPS (średnia) |
-3.03 |
-3.57 |
-3.37 |
-2.16 |
-0.30 |
1.42 |
2.90 |
| Liczba analityków (Przychody) |
4 |
5 |
7 |
7 |
6 |
3 |
3 |
| Liczba analityków (EPS) |
5 |
8 |
8 |
7 |
6 |
2 |
2 |
| symbol |
KALV |
KALV |
KALV |
KALV |
KALV |
KALV |
KALV |